Here are the latest stories being discussed in biopharma today:

Pharmaceutical giants Johnson & Johnson, Pfizer, and Bristol Myers Squibb have downplayed the overall impact of the Inflation Reduction Act on their business, despite initially voicing opposition to the legislation.

AstraZeneca’s cancer drug, Calquence, has achieved its primary endpoint in a Phase 3 trial for first-line mantle cell lymphoma. The drug, coupled with chemotherapy and immunotherapy, led to a significant increase in progression-free survival.

The drug pricing watchdog, Institute for Clinical and Economic Review (ICER), has questioned the integrity of the FDA’s accelerated approval process if it grants full approval to treatments like Sarepta’s gene therapy, which have failed their required confirmatory trials.

Novo Nordisk has stepped ahead of its schedule, securing over a third of the global diabetes market a year early, with the rise from 32.2% to 34% exceeding its strategic aspiration.

Emergent BioSolutions intends to close facilities and lay off 300 employees as part of a new strategy outlined by its recently-appointed CEO, Joe Papa. The actions will ultimately save the company $80 million.

Moderna remains committed to its long-term strategy according to its first-quarter update. However, the company has ended its partnership with Metagenomi.

Further, Novartis is set to acquire Mariana Oncology in a $1B radiopharma deal. Also, FDA seeks additional data on Dupixent in Chronic Obstructive Pulmonary Disease (COPD), a move that could delay a decision. Finally, Senators are questioning if UnitedHealth Group is too big, following a recent cyberattack on the company.